Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

OTHER × Diet Therapy × NET × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 14 Breast 14 Gastrointestinal 13 Other 7 Gynecologic 6 Other hematologic neoplasm 4 Lymphoid 4 Dermatologic 4 CNS 3 Thoracic 2 Plasma cell 2 Head & Neck 2 Sarcoma 1 Other solid neoplasm 1 NET 1 Myeloid 1 Endocrine 1

Conditions

Neuroendocrine Tumors 1

Interventions

lutetium Lu 177 dotatate 29 Everolimus 17 Magnetic Resonance Spectroscopy 13 gallium Ga 68 dotatate 10 Temozolomide 9 Nivolumab 9 Capecitabine 9 177Lu-octreotide, DOTA(0)-Tyr(3)- 8 lanreotide 7 Positron Emission Tomography Computed Tomography 7 Somatostatin 6 Octreotide 6 90Y-octreotide, DOTA-Tyr(3)- 6 pembrolizumab 5 cabozantinib 5 Lutetium-177 5 Fluorodeoxyglucose F18 5 3-Iodobenzylguanidine 5 pasireotide 4 avelumab 4 Ipilimumab 4 Ga(III)-DOTATOC 4 Carboplatin 4 Al18F-NOTA-octreotide 4 telotristat ethyl 3 surufatinib 3 fluorodopa F 18 3 copper dotatate CU-64 3 Surveys and Questionnaires 3 Single Photon Emission Computed Tomography Computed Tomography 3

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT02481804 2024-05-06

DIVIT-pilot

University Medical Center Groningen

Phase NA Completed

Neuroendocrine Tumors

Data powered by HemOnc (CC BY 4.0) Colophon ⚡